Cigarette smoke can activate the alternative pathway of complement in vitro by modifying the third component of complement.
Open Access
- 28 February 1985
- journal article
- research article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 75 (3) , 1000-1007
- https://doi.org/10.1172/jci111760
Abstract
Cigarette smoking is associated with significant increases in the number of pulmonary mononuclear phagocytes and neutrophils. A potent chemoattractant for these cells is C5a, a peptide generated during complement (C) activation. We, therefore, investigated the possibility that cigarette smoke could activate the complement system in vitro. Our results show that factor(s) (mol wt less than 1,000) present in an aqueous solution of whole, unfiltered cigarette smoke can deplete the hemolytic capacity of whole human serum in a dose-dependent manner. The particle-free, filtered gas phase of cigarette smoke is inactive. The smoke factor(s) do not activate serum C1, but do deplete serum C4 activity. Treatment of purified human C3 with whole smoke solution modifies the molecule such that its subsequent addition to serum (containing Mg/EGTA to block the classical pathway) results in consumption of hemolytic complement by activation of the alternative pathway. Smoke-modified C3 shows increased anodal migration in agarose electrophoresis, but this is not due to proteolytic cleavage of the molecule as evidenced by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. In contrast to methylamine-treated C3, C3 treated with smoke is only partially susceptible to the action of the complement regulatory proteins Factors H and I. In addition, smoke-modified C3 has diminished binding to Factor H as compared with methylamine-treated C3. Finally, smoke-modified C3 incorporates [14C]methylamine which suggests that the thiolester bond may be intact. These data indicate that aqueous whole cigarette smoke solution can modify C3 and activate the alternative pathway of complement, perhaps by a previously unrecognized mechanism. Should this occur in vivo, complement activation might partly account for the extensive pulmonary leukocyte recruitment observed in smokers.This publication has 33 references indexed in Scilit:
- THE THIRD (C3) AND THE FOURTH (C4) COMPONENTS OF COMPLEMENT: LABILE BINDING SITE AND COVALENT BOND FORMATIONAnnals of the New York Academy of Sciences, 1983
- Biochemical links between cigarette smoking and pulmonary emphysemaJournal of Applied Physiology, 1983
- Complement Activation by Cigarette Smoke Condensate and Tobacco InfusionArchives of environmental health, 1983
- Pathogenesis of EmphysemaChest, 1983
- Structural characterization of factor I mediated cleavage of the third component of complementBiochemistry, 1982
- Fibronectin fragment(s) are chemotactic for human peripheral blood monocytes.The Journal of Immunology, 1982
- THE RELEASE OF ELASTASE, MYELOPEROXIDASE, AND LYSOZYME FROM HUMAN ALVEOLAR MACROPHAGESPublished by Elsevier ,1982
- Amino acid sequence around the proposed thiolester bond of human complement component C4 and comparison with the corresponding sequences from C3 and α2-macroglobulinBioscience Reports, 1981
- Fourth component of human complement: studies of an amine-sensitive site comprised of a thiol componentBiochemistry, 1981
- Relation of putative thioester bond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement.The Journal of Experimental Medicine, 1980